|Graphic: Cathleen Heard|
"The drug industry has become a victim of its own success," says Kevin Lewis, an equities analyst for pharmaceutical and biotech with William Blair & Co., Chicago. "Just five years ago, companies like Merck and Pfizer were relying on their own internal R&D to develop...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?